

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Ipilimumab (genetical recombination) Nivolumab (genetical recombination)

July 17, 2024

### **Therapeutic category**

Other antitumor agents

### **Non-proprietary name**

Ipilimumab (genetical recombination)

Nivolumab (genetical recombination)

### **Safety measure**

PRECAUTIONS should be revised.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions Encephalitis, meningitis	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions Encephalitis, meningitis, <u>myelitis</u>

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)